Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRECISE, a two arm, double blind randomised controlled trial of pregabalin in addition to usual care compared to placebo with usual care for reducing leg pain in patients with sciatica.

Trial Profile

PRECISE, a two arm, double blind randomised controlled trial of pregabalin in addition to usual care compared to placebo with usual care for reducing leg pain in patients with sciatica.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Pain; Sciatica
  • Focus Therapeutic Use
  • Acronyms PRECISE
  • Most Recent Events

    • 18 Jul 2017 Results published in the Annals of Internal Medicine
    • 31 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 Mar 2017 Primary endpoint (Average leg pain intensity over the last 24 hours measured by the numeral pain rating scale) has not been met, according to the results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top